Bioprocess chromatography resin downstream purification resin biopharma chromatography resin process-scale chromatography resin: How AI is reshaping high-end purification consumables development

If you work in the biopharmaceutical industry, you're probably familiar with these four terms: biological separation media, downstream purification media, biopharmaceutical chromatography media, and industrial chromatography media. They often appear in various reports, bids, and procurement lists. Sometimes it seems like they're talking about the same thing, while other times, each term seems to have its own specific meaning.

Many people often confuse them, but if you look closely, these four terms are actually describing the same core material from four different perspectives — porous microspheres with functional groups, also known as chromatography media/chromatographic resins. The only difference is the perspective behind the naming, ranging from broad to narrow and from low to high technical barrier.

Today, we'll break down these four concepts completely, and also talk about what's happening in this industry, known as the "invisible chip" of biopharma, and how AI protein design is reshaping its R&D logic.

1. Four Types of Chromatography Media: A Four-Tiered System from Broad to Narrow

Let's start with the conclusion: these four terms essentially point to the same core material — matrix microspheres plus surface functional groups, i.e., chromatography media. The difference is only in the definition angle and scope.

From the broadest to the most specific, the progression roughly goes like this:

Biological separation media → Downstream purification media → Biopharmaceutical chromatography media → Industrial chromatography media

The deeper you go, the narrower the scope, but the higher the technical barrier and added value.

First Layer: Biological Separation Media — the Broadest Functional Perspective

"Biological separation media" is the broadest term, emphasizing function: used for separating and purifying biomacromolecules.

Any media used to separate proteins, nucleic acids, polysaccharides, virus particles, and other biomolecules can be classified as biological separation media. Matrix materials include agarose, synthetic polymers, silica, and many other types; separation modes include affinity, ion exchange, hydrophobic interaction, size exclusion, and more.

This term usually appears in the context of industry overviews or technical classifications. For example, the "global biological separation media market size" includes all media used for biological separation — whether for laboratory or industrial use, whether milligram or ton-scale.

Second Layer: Downstream Purification Media — the Process Flow Perspective

"Downstream purification media" is named from the perspective of the biopharmaceutical process flow.

Biopharmaceutical production is divided into upstream and downstream: upstream involves cell culture or fermentation to express the target protein, while downstream involves separating, purifying, and refining the target protein from complex culture solutions to achieve pharmaceutical-grade purity and safety.

Downstream purification media is the collective term for all chromatography media used in the downstream process — affinity capture, ion exchange intermediate purification, hydrophobic aggregate removal, size-exclusion polishing — all fall under downstream purification media.

This term is most used in the contexts of process development and production operations. There’s an industry saying: "Upstream determines yield, downstream determines quality," highlighting the core role of downstream purification media in drug quality and cost control.

Layer 3: Biopharmaceutical Chromatography Media — Compliance Perspective

"Biopharmaceutical chromatography media" is named from the perspective of the application industry and compliance level. Chromatography media have many application scenarios—food processing, environmental monitoring, chemical separation, and research reagents all use them—but biopharmaceuticals are the field with the highest technical requirements, the highest unit price, and the largest market size.

Why are the requirements for biopharmaceuticals the highest? Because the media directly contact the drugs, which are ultimately injected into humans. Therefore, the safety of the media itself, batch consistency, impurity leaching levels, and regulatory compliance (such as having a DMF file) are all subject to extremely strict requirements. Even small differences in separation performance can affect drug quality and patient safety.

This term appears most often in discussions about industry analysis and supply chain security. For example, "domestic substitution of biopharmaceutical chromatography media" refers to the import substitution process for this high-end market.

Layer 4: Industrial Chromatography Media — Scale Perspective

"Industrial chromatography media" emphasizes scale and level, corresponding to laboratory-grade and analytical-grade media. Media used in the lab may come in milliliter sizes or pre-packed columns, with relatively loose requirements for mechanical strength and batch consistency. Industrial chromatography media, on the other hand, must fit into chromatography columns of hundreds, thousands, or even tens of thousands of liters and be produced continuously under GMP conditions. They must meet three core hard metrics:

l Mechanical stability: able to withstand 0.3~1.0 MPa operating backpressure (depending on the matrix type), support 50~500 cm/h linear flow rates, and adapt to short-cycle, large-scale production needs;

l Alkali regeneration performance: compatible with industrial Clean-in-place (CIP) in situ cleaning processes and able to be regenerated hundreds of times;

l Batch reproducibility: critical performance parameters (particle size distribution, dynamic binding capacity, ligand density, etc.) must have inter-batch relative standard deviation (RSD) ≤5%, ensuring process stability and repeatability.

Many companies can produce lab-scale media, but globally, only a few can reliably supply industrial-grade chromatography media. This is the highest technical barrier level and currently the core battleground for domestic substitution.

2. Five Main Functional Types of Chromatography Media: The Family of Media for Downstream Purification

 The Five Principles of Chromatography

After going through the hierarchy of the four names, let's quickly go over the five major functional types of chromatography resins—these are the types of resins that downstream purification processes rely on to gradually ‘fish out’ the target protein.

Affinity chromatography resins—the most specific 'catcher.' The principle is that the ligand specifically binds to the target protein, like a key fitting a lock. The most typical example is Protein A affinity resin, which specifically binds the Fc region of antibodies, allowing antibodies to be grabbed straight from the culture medium in one step, with purity exceeding 95%. This is also the most valuable and technically challenging type.

Ion exchange chromatography resins—the most versatile 'selector.' They separate proteins based on surface charge differences, with cation and anion exchange types. Very versatile, high capacity, and relatively low cost, almost all protein purification processes use them. In the three-step antibody purification method, ion exchange is usually used in the second intermediate purification and the third polishing step.

Hydrophobic interaction chromatography resins—the 'cleaner' for aggregates. They separate proteins based on hydrophobic surface differences, binding under high salt conditions and eluting when salt concentration decreases. Their main purpose is to remove antibody aggregates because aggregates have a larger hydrophobic surface, bind more strongly, and elute later.

Multimodal (mixed-mode) chromatography resins—the flexible 'all-rounder.' They have two or more mechanisms of action, such as ion exchange and hydrophobic interaction. They offer unique selectivity and can handle complex samples that are hard to separate with conventional resins, increasingly used in purifying new molecules like bispecific antibodies, ADCs, and fusion proteins.

Gel filtration (size-exclusion) chromatography resins—the 'referee' that lines things up by size. They separate purely by molecular size; big molecules can’t enter the pores and come out directly, while small molecules take longer paths and elute later. Preparative SEC has low capacity and long processing times, mostly used for final polishing of a few high-value molecules; analytical SEC is the gold standard for detecting antibody aggregates and fragments; desalting SEC resins are widely used in industrial buffer exchange steps.

3. Industry Market Landscape: A Hundred-Billion-Yuan Track Dominated by Oligopolies, Domestic Substitution Accelerates

Global and domestic market scale (data source: QYResearch, Qianzhan Industry Research Institute 2026 Industry Report)

1. Full-category bioprocessing media: The global market size is expected to reach $12.87 billion in 2025, up 7.2% year-on-year; among them, protein purification-specific resins account for $8.26 billion, with monoclonal antibody (mAb) purification demand making up 47.3% of the total; the market for specialized chromatography resins is projected to be $1.951 billion in 2025 and reach $3.212 billion by 2032, with a CAGR of 7.4%.

2. China’s market leads in growth: In 2025, China’s domestic biopharmaceutical chromatography media market will reach 10.8 billion RMB, with an expected 13.2 billion RMB in 2026; the total full-category bioprocessing resin market will surpass 22 billion RMB in 2025, increasing its share of the global market to 17.3%. Affinity resins are the biggest segment for domestic substitution.

3. Growth fundamentals: According to Sullivan's "2026 Global Antibody Drug Blue Book," the global therapeutic antibody market was $254.3 billion in 2024 and is expected to exceed $675.7 billion by 2035. Commercial mAb production capacity continues to expand, driving rigid demand for chromatography resins.

Industry Competition and Status of Domestic Substitution

The global market is highly concentrated, with the top ten overseas manufacturers holding a combined 71% market share in 2025. Cytiva and Merck have long monopolized high-end Protein A industrial resins. Imported products are expensive and have 6–8 month delivery cycles, posing supply chain risk.

Domestic technology continues to advance: In 2025, domestic penetration of chromatography resins reached 41%; for clinical R&D projects, domestic selection rate is 68.5%, but domestic share in GMP large-scale commercial production is only 28.9%. High-end alkaline-resistant affinity ligands still heavily depend on imports, which is a core bottleneck in the industry.

4. Triple Technical Barriers of Industrial Chromatography Resins and Traditional R&D Bottlenecks

Chromatography media is considered a key consumable in biomanufacturing. The core barriers are divided into three layers: hardware matrix, ligand modification, and regulatory validation. Combined with efficiency limitations of traditional R&D models, these factors jointly restrict the domestic advancement of high-end products.

Stage One: Preparation of matrix microspheres. Achieving highly uniform particle size, even pore distribution, sufficient mechanical strength, and low nonspecific adsorption is extremely challenging. Even a few microns' deviation in microsphere size or a slightly wider pore distribution can drastically reduce separation performance. The process for producing highly monodisperse, precisely controlled pore size, highly cross-linked agarose microspheres has long been a core technological barrier for overseas companies.

Stage Two: Surface modification and ligand coupling. Making the microspheres is just the beginning. You need to evenly modify the microsphere surface with functional groups, then stably, directionally, and densely couple the ligands on—that’s all part of the process know-how. Even with the same Protein A ligand, different coupling methods can result in huge differences in loading capacity, lifespan, and shedding levels.

Stage Three: Regulatory compliance and validation. The resin directly contacts drugs, so regulatory requirements are extremely strict. For a resin to enter commercial production, a large amount of validation is needed—physicochemical properties, protein binding capacity, impurity leaching, cleaning validation, lifespan studies… Once a product enters Phase III clinical trials or commercialization, changing the resin supplier is considered a significant process change by regulators, requiring a full set of comparability validations and filings. This makes it very costly and sticky for customers to switch suppliers.

On top of all these barriers, there’s an even bigger pain point: the bottleneck in the R&D model. Traditional ligand modification is too slow. From discovery to mature optimization, an industrial-grade ligand can take 2–5 years, with high costs, low screening efficiency, and heavy reliance on expert experience. Optimizing ligand protein stability, alkali resistance, and loading performance is very challenging, and conventional iterations often hit a performance ceiling. Moreover, lab-scale R&D results can’t be quickly adapted to industrial-scale production, so excellent lab performance might not translate into stable large-scale production.

This greatly limits the advancement and industrialization of domestic resins.

5. AI Protein Design Reshaping Resin R&D: The MatwingsVenus™ (XiaoWu™) Closed-Loop Wet and Dry Implementation Practice

 AI Closed-Loop Research and Development Cycle for Dry and Wet Processes

Addressing the traditional R&D bottlenecks in the industry, AI protein design technology is providing brand-new solutions for the precise iteration and performance upgrades of bioseparation media, biopharmaceutical chromatography media, and industrial chromatography media.

5.1. Research&Design Efficiency: From “2–5 years” to “2–6 months”

Traditional media ligand development relies heavily on experimental trial-and-error, which is time-consuming and costly. The new generation of AI-driven protein design platforms, leveraging billions of protein sequences and multi-objective optimization algorithms, can make zero-shot predictions and efficiently iterate with small sample sizes. This allows for accurate forecasting of how protein mutations will affect ligand stability, binding capacity, and alkali resistance without extensive wet lab experiments. As a result, the R&D cycle is drastically reduced from the conventional 2–5 years to just 2–6 months.

5.2. Performance Implementation: Targeted Optimization of Core Industrial Indicators

AI can specifically optimize the core industrial indicators of media, effectively enhancing alkali stability, dynamic binding capacity, and service life. For example, Matwings Technology’s MatwingsVenus™ (Xiaowu™) platform, which uses an AI-driven wet-dry closed-loop R&D system, has achieved a 4-fold improvement in single-domain antibody ligand alkali resistance and doubled the media’s service life. The optimized industrial chromatography media can be scaled up to 5,000-liter production scenarios and is the world’s first AI-designed chromatography media technology system realized for large-scale industrial production. In 2024, Matwings Technology collaborated with Gensai Pharma to develop high-alkali-resistant affinity media using AI large models, successfully evolving single-domain antibodies into industrial-grade alkali-resistant affinity media and achieving industrial-scale production at 5,000 liters.

5.3. Custom Adaptation: Precisely Matching Downstream Purification Needs Across Scenarios

For new biologic molecules such as bispecific antibodies, ADCs, VHH nanobodies, and fusion proteins, traditional methods for developing exclusive affinity ligands are extremely costly and time-consuming. AI can design or optimize highly specific ligands from scratch based on the target protein’s structural information—without relying on animal immunization or building large screening libraries. The platform can tailor ligand specificity and separation selectivity for different biomolecules like antibodies and recombinant proteins, effectively reducing impurities such as aggregates and fragments, while balancing the precision of small-scale R&D with the stability and cost-effectiveness of industrial-scale production. This fully covers all scenarios in bioseparation, downstream purification, pharmaceutical compliance, and industrial-scale production.

6.Industry Outlook: AI-Driven Upgrades for Domestic Chromatography Media Industrialization

With the rapid development of the biopharmaceutical industry, the requirements for downstream purification processes have shifted from 'basic separation' to new industrial standards of 'high performance, long lifespan, low cost, high adaptability, and scalability.' The domestic high-end iteration of bioprocessing resins, downstream purification resins, biopharmaceutical chromatography resins, and industrial chromatography resins has become a core trend for high-quality development in the industry.

The deep integration of AI technology with bioprocess resin R&D is breaking the limitations of traditional technological iterations. Domestic chromatography resins are making the leap from 'experience-based R&D' to 'intelligent, precise R&D,' effectively addressing key pain points like insufficient industrial resin performance, batch instability, long R&D cycles, and high costs. In the future, with the continuous iteration of AI-driven closed-loop wet and dry R&D systems, more high-performance, customized, and industrialized biopharmaceutical chromatography resins will be applied in practice, continuously enhancing quality and efficiency across the entire biopharmaceutical industry chain, and helping the domestic biopharmaceutical industry move toward a higher-quality stage of industrialization, compliance, and internationalization.